yahoo_financeOriginal article
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Phase 2ACR-2316Positive
AI Analysis
Summary
Acrivon advanced ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, into randomized dose expansion in its ongoing Phase 1/2 study.
Clinical Trial Data
Phase
1/2
Outcome Details
Advancement into randomized dose expansion phase
Importance:5/10
Sentiment:
0.60
clinical_developmentphase_1_2WEE1_inhibitorPKMYT1_inhibitorfirst_in_class
Related Companies
Read the original article
Published by yahoo_finance on August 5, 2026 12:30 PM